NEW YORK, NY, Sep 27, 2011 (MARKETWIRE via COMTEX) Oracle
News Facts
-- To support more personalized, value-based healthcare, Oracle today
announced the introduction of Oracle Health Sciences Translational
Research Center, a platform that facilitates the secondary use of
healthcare data for both clinical and research organizations.
-- Oracle Health Sciences Translational Research Center enables
pharmaceutical and biotech companies, contract research organizations,
as well as academic research organizations to normalize, aggregate and
analyze data from numerous internal and external sources to identify
new predictive biomarkers, best practices for diagnosis and treatment
and more effective and safe therapies for individuals.
-- A key component of the solution, Oracle Health Sciences Cohort
Explorer, helps identify and aggregate patients with similar clinical
attributes and puts powerful and easy-to-use analytics directly in the
hands of researchers and clinicians, enabling them to be
self-sufficient and timely in their analyses, while ensuring a secure
foundation that delivers high levels of access control and
traceability to support security and regulatory compliance
requirements.
-- To speed time to value and reduce IT complexity and cost, the fully
integrated solution is built on Oracle's proven life sciences and
enterprise healthcare analytics solutions. These include Oracle
Healthcare Data Warehouse Foundation, a comprehensive and detailed
healthcare data model that ensures high quality clinical data is
readily accessible to researchers, and Oracle Health Sciences Clinical
Development Center, which provides detailed traceability of analysis
processes, as well as comprehensive audit capabilities to facilitate
regulatory compliance.
-- The initial release focuses on enabling the aggregation, normalization
and analysis of clinical information, such as electronic health record
data. It will help health sciences organizations gain insights into
how specific patient populations respond to treatments with:
-- Support for more than 300 search criteria, such as patient
demographics, diagnosis, and medication
-- Flexible, real-time queries that enable iterative hypothesis
testing essential for translational research
-- 37 pre-built operational reports to increase efficiency
-- Seven pre-built dashboards and a flexible and extensible data
model that enables rapid development of additional reports and
views
-- A standardized framework that integrates and manages disparate
pre-existing command-line applications, scripts and algorithms
commonly used in translational research
-- To ensure that the new platform meets the needs of health sciences
organizations, Oracle worked closely with numerous development
partners, including Merck, Roche, Erasmus University Medical Center,
Inova Health System, Moffitt Cancer Center, and Oregon Health &
Science University (OHSU) Knight Cancer Institute.
-- The solution has been benchmarked on millions of patient records --
demonstrating scalability for large-scale applications.
Supporting Quotes
-- "Oracle Health Sciences Translational Research Center, developed in
cooperation with leading healthcare organizations, academic research
centers, and biopharmaceutical companies, is a productized,
ready-to-deploy system to help enable effective personalized
healthcare," said Neil de Crescenzo, senior vice president and general
manager, Oracle Health Sciences. "It offers an integrated solution,
built on a proven, scalable and secure platform, that enables all key
stakeholders -- including researchers, physicians, other clinicians
and biostatisticians -- to optimize each of their unique roles in the
translational research continuum."
-- "Oracle Health Sciences Translational Research Center will support
health sciences organizations, like the Knight Cancer Institute, as we
collectively work to ensure that the patient remains at the center of
research and care," said Brian Druker, M.D., director of the OHSU
Knight Cancer Institute. "The ability to aggregate data, normalize it,
and most importantly, effectively analyze it to yield previously
unavailable insight is essential to unlocking the potential of
personalized medicine."
-- "Scientific discovery in healthcare continues at an unprecedented
pace, and we find ourselves on the cusp of enabling full-scale
translational medicine. At Moffitt we created the foundation for this
through our Total Cancer Care(TM) program which combines one of the
largest cancer biorepositories with the collection of longitudinal
clinical data. The key is mining this data for insight, putting the
power to do so in the hands of the researchers who are closest to the
work -- and doing this in a cost-effective manner," said Mark Hulse,
R.N., vice president of Information Services and chief information
officer of Moffitt. "Oracle has been a key partner with us in this
effort and we believe that Oracle Health Sciences Translational
Research Center will further advance the ability to deliver on these
requirements."
Supporting Resources
-- Oracle in Health Sciences
-- Follow Oracle Health Sciences on Twitter
-- Join the Oracle Health Sciences Community on Facebook
-- Oracle Health Sciences on YouTube
-- Prix Galien USA
About Oracle
Oracle is the world's most complete, open, and integrated business software and hardware systems company. For more information about Oracle, please visit our Web site at http://www.oracle.com .
Trademark
Oracle and Java are registered trademarks of Oracle. Other names may be trademarks of their respective owners.
Disclaimer
THIS DOCUMENT IS FOR INFORMATIONAL PURPOSES ONLY AND MAY NOT BE INCORPORATED INTO A CONTRACT OR AGREEMENT.
Contact Info
Greg Lunsford
Oracle
+1.650.506.6523
Email Contact
Mary Tobin
O'Keeffe & Company
+1.503.658.7396
Email Contact
SOURCE: Oracle Corporation